乳腺癌患者手术前后相关实验室数据的检测意义

The significance of correlation laboratory examination in breast cancer patients before and after operation

目的探讨乳腺癌患者手术前后可溶性细胞膜糖蛋白(Endoglin)、血管内皮生长因子(VEGF)、表皮生长因子受体(EGFR)的水平变化,分析可溶性Endoglin、VEGF和EGFR水平检测在乳腺癌患者中的临床意义。方法选取2016年10月至2018年9月在该院进行手术的乳腺癌患者52例作为观察组,以同期健康体检者50例作为对照组,分别检测观察组手术前后和对照组可溶性Endoglin、VEGF和EGFR水平,并对数据进行比较分析。结果观察组患者手术前可溶性Endoglin、VEGF和EGFR表达水平均明显高于对照组,差异均有统计学意义(P<0.05);观察组患者手术前可溶性Endoglin、VEGF和EGFR表达水平均明显高于手术后,差异均有统计学意义(P<0.05);观察组患者手术后可溶性Endoglin、VEGF和EGFR表达水平与对照组比较,差异均无统计学意义(P>0.05)。结论在乳腺癌患者中,存在可溶性Endoglin、VEGF和EGFR表达水平异常,可溶性Endoglin、VEGF和EGFR水平检测对乳腺癌患者手术前后的病情观察及预后有一定临床应用价值。

Objective To investigate the changes of soluble cell membrane glycoprotein(Endoglin),vascular endothelial growth factor(VEGF),epidermal growth factor receptor(EGFR)in breast cancer patients,and to analyze its clinical significance.Methods A total of 52 breast cancer patients operated in the hospital from October 2016 to September 2018 were selected as the observation group,and 50 healthy people who underwent the physical examination in the same period were selected as the control group.The levels of soluble Endoglin,VEGF and EGFR of observation group before and after the operation and control group were detected,and the data were compared and analyzed.Results The levels of soluble Endoglin,VEGF and EGFR in the observation group before the operation were significantly higher than those in the control group,and the differences were statistically significant(P<0.05).The levels of soluble Endoglin,VEGF and EGFR before the operation in the observation group were significantly higher than those after the operation,and the differences were statistically significant(P<0.05).There was no statistically significant difference between the the levels of soluble Endoglin,VEGF and EGFR in the observation group and in the control group(P>0.05).Conclusion The levels of soluble Endoglin,VEGF and EGFR were abnormal in the breast cancer patients and it might be the indexes for monitoring the clinical disease condition and judging the prognosis of the breast cancer.